在美国食品及药物管理局（FDA）批准了Ocugen公司提交的新药研究申请后，一种利用圣路易斯华盛顿大学技术开发的鼻腔COVID-19疫苗将在美国开始第一阶段临床试验。 Ocugen公司是一家美国生物技术公司，于2022年从华盛顿大学获得了这项技术的许可权。该试验将由美国国立卫生研究院（NIH）下属的国立过敏与传染病研究所（NIAID）负责和赞助。 FDA的批准标志着一个重要的里程碑，为今年春季启动 ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

U.S. medical services providers are seeing the greatest numbers of flu cases since the 2009-2010 flu season, the Centers for ...

The latest numbers from the Montana Department of Public Health and Human Services show a 53% increase in weekly influenza ...

With the acute phase of the Covid-19 pandemic fading even as the coronavirus persists and evolves, a new normal is taking shape around the world. But there have been plenty of other illnesses to ...

Even a mild infection with COVID-19 can promote clogged arteries, increasing the risk of heart attack in some people, a new ...

Ex-CNN editor Chris Cilizza conceded on Monday that he "screwed up" in his assessment of the lab leak theory, suggesting that ...

States are absorbing substantial increases in healthcare costs for the poor, as they realize that the people remaining on ...

A new study linked COVID-19 with the rapid growth of plaque in the coronary arteries. This plaque is a high-risk type prone ...

Citing unverified data, Robert F. Kennedy Jr. claimed in December 2021 that the Covid-19 vaccine was the “deadliest vaccine ...

Unlimited access to premium stories for as little as $12.95 /mo.